Rituximab-induced Acute Thrombocytopenia in a Patient with Follicular Lymphoma: A Case Report and Review of the Literature

被引：17

作者：

Omura, Yoshiyuki ^{[1
]}

Shimazu, Hiroshi ^{[1
]}

Takahashi, Tsuyoshi ^{[1
]}

机构：

[1] Mitsui Mem Hosp, Dept Hematol, Tokyo, Japan

来源：

INTERNAL MEDICINE | 2018年 / 57卷 / 08期

关键词：

rituximab; acute thrombocytopenia; follicular lymphoma; LEUKEMIA; INFUSION; THERAPY;

D O I：

10.2169/internalmedicine.9628-17

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Rituximab is a highly effective agent that is used in the treatment of B-cell lymphoma. Rituximab-induced acute thrombocytopenia is a rare side effect that has previously been reported in a small number of patients with malignant lymphoma; its mechanism is still unknown. We herein report the case of a 74-year old man who was diagnosed with follicular lymphoma and who developed severe acute thrombocytopenia the day after the administration of rituximab. Coagulation abnormality, which mimicked disseminated intravascular coagulation, also appeared. When physicians use rituximab to treat high-risk patients, the platelet count should be closely monitored to avoid possible adverse events.

引用

收藏

页码：1151 / 1154

页数：4

相关论文

共 21 条

[1] Rituximab-Induced Severe Acute Thrombocytopenia: A case Report and Review of Literature [J].

Dhand, Suneel ;

Bahrain, Huzefa .

CANCER INVESTIGATION, 2008, 26 (09) :913-915

[2] Rituximab-induced acute thrombocytopenia: an underappreciated entity [J].

El-Osta, Hazem ;

Nair, Binu .

LEUKEMIA & LYMPHOMA, 2013, 54 (12) :2736-2737

[3] Anti-CD20 antibody treatment of non-Hodgkin lymphomas [J].

Engelhard, Marianne .

CLINICAL IMMUNOLOGY, 2016, 172 :101-104

[4] Rituximab-induced thrombocytopenia: a cohort study [J].

Giezen, Thijs J. ;

Mantel-Teeuwisse, Aukje K. ;

ten Berg, Maarten J. ;

Straus, Sabine M. J. M. ;

Leufkens, Hubert G. M. ;

van Solinge, Wouter W. ;

Egberts, Toine C. G. .

EUROPEAN JOURNAL OF HAEMATOLOGY, 2012, 89 (03) :256-266

[5] Severe thrombocytopenia and fibrinolysis mimicking disseminated intravascular coagulation after rituximab infusion [J].

Kotsianidis, Ioannis ;

Goutzouvelidis, Aggelos ;

Anastasiades, Athanasios ;

Bouchliou, Irene ;

Nakou, Evangelia ;

Spanoudakis, Emmanouil ;

Christophoridou, Anna V. ;

Margaritis, Dimitrios ;

Bourikas, George ;

Tsatalas, Costas .

AMERICAN JOURNAL OF HEMATOLOGY, 2010, 85 (02) :146-146

[6]

Larrar Sophie, 2006, Haematologica, V91, pECR36

[7] Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance [J].

Manshouri, T ;

Do, KA ;

Wang, XM ;

Giles, FJ ;

O'Brien, SM ;

Saffer, H ;

Thomas, D ;

Jilani, I ;

Kantarjian, HM ;

Keating, MJ ;

Albitar, M .

BLOOD, 2003, 101 (07) :2507-2513

[8] Rituximab chimeric Anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma:: Half of patients respond to a four-dose treatment program [J].

McLaughlin, P ;

Grillo-López, AJ ;

Link, BK ;

Levy, R ;

Czuczman, MS ;

Williams, ME ;

Heyman, MR ;

Bence-Bruckler, I ;

White, CA ;

Cabanillas, F ;

Jain, V ;

Ho, AD ;

Lister, J ;

Wey, K ;

Shen, D ;

Dallaire, BK .

JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (08) :2825-2833

[9]

Otrock Zaher K, 2005, Haematologica, V90 Suppl, pECR23

[10] Rituximab-induced acute thrombocytopenia in a patient with prolymphocytic leukemia [J].

Pamuk, GE ;

Donmez, S ;

Turgut, B ;

Demir, M ;

Vural, O .

AMERICAN JOURNAL OF HEMATOLOGY, 2005, 78 (01) :81-81